In the February 2015 issue of World Psychiatry, gave an overview of novel psychoactive substances and their potentially harmful effects. They highlighted that in the last couple of years the number of drugs offered via Internet shops has increased dramatically and that benzodiazepines are often used to treat intoxications with these drugs in the clinical setting.
https://www.skookums.net/benzodiazepines would like to point out that designer benzodiazepines have become a rapidly growing class of drugs of abuse in their own right in the last two years. We believe that mental health professionals should be aware of this new development.
The first designer benzodiazepines available online were diclazepam, flubromazepam and pyrazolam. Recently, five others became readily available none of which has been approved for medicinal use in any country. Nearly all of these compounds have been synthesized as drug candidates by pharmaceutical companies and their syntheses, as well as basic animal testing data, are described in the literature along with many more potential successors. Typical formulations are tablets, capsules or blotters in various doses. Furthermore, the drugs are also offered as pure powders with prices as low as 5-10 US cents per dose.
Immunochemical tests applied in clinical settings and drug rehabilitation detect most of the designer benzodiazepines with sufficient sensitivity. However, the mass spectrometric methods needed for confirmation do not regularly cover the latest designer benzodiazepines, due to lack of reference materials. Practitioners should be aware of this limitation and carefully assess seemingly “false-positive” results.
Mainly because of their high strength, compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5magnesium. Such low doses are exceedingly difficult to measure for users handling bulk materials, and tablets often fluctuate greatly in the content of the active component.
This can lead to unintended overdosing, and could end up being of concern in drug facilitated crimes.
Developer benzodiazepines are usually taken as “self-medication” by users of stimulant and hallucinogenic drugs, leading to “upper blue cycles” and risk of severe craving in people frequenting the party field. Persons with anxiety disorders also tend to self-medicate on these drugs when a medical prescription cannot be obtained. The high supply of these drugs via online vendors and the low price may help development of habit in this population.
Many “classical” benzodiazepines are listed in Schedule 4 of the 1971 UN Convention that they are also in Timetable IV of the Circumstance. S. Controlled Substances Take action, but it is ambiguous if designer benzodiazepines are covered by the Regulated Substances Analogue Enforcement Take action, 1986. Similar legal problems exist in most other countries on the earth, rendering it difficult to reduce accessibility to these dangerous new drugs.